CFO of Repligen Corp (30-Year Financial, Insider Trades) Jon Snodgres (insider trades) sold 3,545 shares of RGEN on 03/04/2021 at an average price of $192.47 a share. The total sale was $682,306.
Repligen Corp is a bioprocessing company developing, producing and commercializing biologic drugs. The company offers its products to life science companies, global biopharmaceutical companies, and contract manufacturers worldwide. Repligen Corp has a market cap of $9.94 billion; its shares were traded at around $181.480000 with a P/E ratio of 163.50 and P/S ratio of 26.75. Repligen Corp had an annual average EBITDA growth of 27.30% over the past 5 years.
CEO Recent Trades:
- CEO Anthony Hunt sold 21,900 shares of RGEN stock on 03/04/2021 at the average price of $190.19. The price of the stock has decreased by 4.58% since.
CFO Recent Trades:
- CFO Jon Snodgres sold 3,545 shares of RGEN stock on 03/04/2021 at the average price of $192.47. The price of the stock has decreased by 5.71% since.
Directors and Officers Recent Trades:
- Senior VP, R&D Ralf Kuriyel sold 2,075 shares of RGEN stock on 03/04/2021 at the average price of $192. The price of the stock has decreased by 5.48% since.
- Director Thomas F Jr Ryan sold 1,000 shares of RGEN stock on 03/03/2021 at the average price of $205. The price of the stock has decreased by 11.47% since.
For the complete insider trading history of RGEN, click here
.
